Extended Data Fig. 7 |. In vivo expansion and memory generation.

a, Flow cytometry analysis showing in vivo expansion of tEGFR⁺ CD19-BBz(86) CAR T cells in the peripheral blood of representative patients who achieved complete remission (patient BZ021) or had progressive disease (patient BZ013). b,c. qPCR showing in vivo CAR T cell expansion and persistence in the blood of patients who achieved complete or partial remission (patients BZ015, BZ016, BZ019, BZ020, BZ021, BZ024 and BZ025) (b) or had progressive disease (patients BZ017, BZ022 and BZ023) (c). d, Memory phenotype (CD45RA⁻ CCR7⁺) of in vivo-expanded tEGFR⁺CD3⁺ CD19-BBz(86) CAR T cells and tEGFR⁻CD3⁺ normal T cells from six patients who had progressive disease (BZ013) or achieved partial remission (BZ014) or complete remission (BZ015, BZ019, BZ020 and BZ021). e, Percentage of CD45RA⁺ and CD45RA⁻ subpopulations of in vivo-expanded tEGFR⁺CD3⁺ CD19-BBz(86) CAR T cells and tEGFR⁻CD3⁺ normal T cells from the six treated patients. P values were calculated from two-tailed Student’s t tests. Horizontal lines denote median values. f, Percentage of CD45RA⁺CCR7⁻, CD45RA⁺CCR7⁺, CD45RA⁻CCR7⁻ and CD45RA⁻CCR7⁺ subpopulations of in vivo-expanded tEGFR⁺CD3⁺ CD19-BBz(86) CAR T cells and tEGFR⁻CD3⁺ normal T cells from the six treated patients. P values were calculated from two-tailed Student’s t tests. Horizontal lines denote median values. g–j, Detection of tEGFR⁺CD3⁺ CD19-BBz(86) CAR T cells in the peripheral blood of patient BZ015 on day 317 after cell infusion. g, Of the tEGFR⁺CD3⁺ CAR T cells, 96.7% were CD8⁺. h, CD19⁺ B cells were still depleted. i, 45.8% of the long-term, persistent tEGFR⁺CD3⁺ CD19-BBz(86) CAR T cells were CD45RO⁺CCR7⁺ central memory T cells in the peripheral blood of patient BZ015 on day 317 after cell infusion, while only 6.25% of the tEGFR⁻CD3⁺ normal T cells were CD45RO⁺CCR7⁺ central memory T cells. j, qPCR analyses in triplicate also showed long-term persistence of CD19-BBz(86) CAR T cells in peripheral blood.